CATX - Perspective Therapeutics, Inc. News

Perspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Pat

SFT is a rare cancer for which patients with locally advanced unresectable or metastatic disease hav

Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult

SEATTLE, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compa

Perspective Therapeutics (NYSEAMERICAN:CATX) Given “Buy” Rating at BTIG Research

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report)'s stock had its "buy" rating reiterat

BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maint

Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANET

SEATTLE, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compa

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Stock Now Rated “Buy” by Sell-Side Analysts

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) has received an average recomme

Perspective Therapeutics Reveals Acceptance Of [212Pb]VMT01 Data For Presentation At SITC 2026

Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us,

Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026

SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compa

Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other

Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket

Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several sma

This $3 Biotech Could Be Worth $11.45, Analyst Says

Perspective Therapeutics Inc. (NYSE:CATX) could benefit from growing interest in radiopharmaceutical

This $3 Biotech Could Be Worth $11.45, Analyst Says

William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radio

William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating

William Blair analyst Andy Hsieh initiates coverage on Perspective Therapeutics (AMEX:CATX) with

Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperf

Perspective Therapeutics Enters Clinical Trial Collaboration With Merck To Combine Its PSV359 With K

Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us,

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluat

SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Comp

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-

SEATTLE, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Comp

seekingalpha.com

Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans

Perspective Therapeutics remains a “Strong Buy,” driven by durable clinical data and multiple near-t

BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price T

BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) wit

B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5

B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Ne

Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATX

Dimensional Fund Advisors LP raised its holdings in Perspective Therapeutics, Inc. (NYSEAMERICAN:CAT

Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $14

Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight

Perspective Therapeutics Q2 EPS $(0.22) Beats $(0.26) Estimate, Sales $81.000K Miss $83.154K Estimat

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.22) per share which beat the a

zacks.com

Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?

Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared t

zacks.com

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Medical sector earnings are off to a strong start, and four biotech companies are positioned to pote

Perspective Therapeutics, Inc. $CATX Shares Bought by Avidity Partners Management LP

Avidity Partners Management LP grew its stake in shares of Perspective Therapeutics, Inc. (NYSEAMERI

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Res

SEATTLE, July 31, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Com

zacks.com

Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Perspective Therapeutics

Ally Bridge Group NY LLC Makes New Investment in Perspective Therapeutics, Inc. $CATX

Ally Bridge Group NY LLC acquired a new position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CAT

ADAR1 Capital Management LLC Purchases 654,142 Shares of Perspective Therapeutics, Inc. $CATX

ADAR1 Capital Management LLC boosted its position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CA

Perspective Therapeutics Receives European Commission Orphan Designation For VMT-α-NET To Treat Gast

The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP)

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET

SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compa

Perspective Therapeutics' Updated Data On Its [212Pb]VMT-α-NET Program Accepted For Presentation At

Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us,

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Co

SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compa

Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

U.S. stock futures mixed, Nasdaq 100 up 100 pts. Telefonaktiebolaget LM Ericsson falls 9.2% in pre-m

Perspective Doses First Brain Tumor Patient in Radiopharmaceutical Study, Expands Cancer Drug Trial

Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us,

Perspective Therapeutics Reports Early Response SignalS And Favorable Safety Across Three Radiopharm

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirm

Perspective Therapeutics Announces That The First Patients Were Dosed In Two New Cohorts Of Phase 1/

The first patient was treated with [212Pb]VMT-α-NET in a fourth cohort of the Company's ongoing

Perspective Therapeutics Q1 EPS $(0.25) Beats $(0.31) Estimate, Sales $76.000K Miss $136.917K Estima

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.25) per share which beat the a

Earnings Scheduled For May 11, 2026

Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperf

BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maint

Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperf

Perspective Therapeutics Reports 72% Of Patients Alive Without Disease Progression In Early Cancer T

Perspective Therapeutics, Inc. ("Perspective" or the "Company) (NYSE:CATX), a radiopharm

HC Wainwright & Co. Maintains Buy on Perspective Therapeutics, Raises Price Target to $13

HC Wainwright & Co. analyst Robert Burns maintains Perspective Therapeutics (AMEX:CATX) with

B. Riley Securities Maintains Buy on Perspective Therapeutics, Raises Price Target to $13

B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy an

UBS Maintains Buy on Perspective Therapeutics, Raises Price Target to $8

UBS analyst David Dai maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the pr

Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperf

Perspective Therapeutics To Present Updated [212Pb]VMT-α-NET Data At AACR 2026

Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radio